Tagrisso-话题@MedSci - 梅斯（MedSci）

#Tagrisso#

14篇内容 | 1220人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1385805, encodeId=0b84138580573, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, objectType=article, longId=206510, objectId=103720651045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=103720651045, replyNumber=0, likeNumber=78, createdTime=2021-02-02, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=103720651045, moduleTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=103720651045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385804, encodeId=53e0138580439, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=阿斯利康的Tagrisso在美国被批准作为NSCLC的辅助疗法, objectType=article, longId=204703, objectId=fb3e204e03ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb3e204e03ee, replyNumber=0, likeNumber=80, createdTime=2020-12-21, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb3e204e03ee, moduleTitle=阿斯利康的Tagrisso在美国被批准作为NSCLC的辅助疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb3e204e03ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385803, encodeId=54131385803a9, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效, objectType=article, longId=192016, objectId=e03e1920168c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e03e1920168c, replyNumber=0, likeNumber=58, createdTime=2020-04-13, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e03e1920168c, moduleTitle=III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e03e1920168c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385802, encodeId=a093138580282, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌, objectType=article, longId=178988, objectId=c2d11e898883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d11e898883, replyNumber=0, likeNumber=73, createdTime=2019-09-07, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d11e898883, moduleTitle=NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c2d11e898883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385801, encodeId=b9af138580145, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=中国监管机构批准阿斯利康的Tagrisso作为EGFR突变型NSCLC的一线治疗药物, objectType=article, longId=178850, objectId=de591e885009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de591e885009, replyNumber=0, likeNumber=66, createdTime=2019-09-06, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de591e885009, moduleTitle=中国监管机构批准阿斯利康的Tagrisso作为EGFR突变型NSCLC的一线治疗药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=de591e885009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385800, encodeId=b739138580067, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=96, createdTime=2019-08-12, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385799, encodeId=2ffe1385e99d2, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=AZ的肺癌药物Tagrisso在欧洲获准作为一线用药, objectType=article, longId=136956, objectId=140b136956f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=140b136956f9, replyNumber=0, likeNumber=57, createdTime=2018-05-03, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=140b136956f9, moduleTitle=AZ的肺癌药物Tagrisso在欧洲获准作为一线用药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=140b136956f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385798, encodeId=50ba1385e9855, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=AZ的Tagrisso作为肺癌一线用药在美国获批, objectType=article, longId=136059, objectId=719a136059b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719a136059b9, replyNumber=0, likeNumber=80, createdTime=2018-04-22, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719a136059b9, moduleTitle=AZ的Tagrisso作为肺癌一线用药在美国获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=719a136059b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385797, encodeId=578e1385e978f, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=AZ的Tagrisso对肺癌的治疗具有持续作用, objectType=article, longId=135565, objectId=8de113556507, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8de113556507, replyNumber=0, likeNumber=84, createdTime=2018-04-18, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8de113556507, moduleTitle=AZ的Tagrisso对肺癌的治疗具有持续作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8de113556507)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385796, encodeId=2fd71385e9619, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=FDA对阿斯利康肿瘤治疗的Tagrisso进行优先审查, objectType=article, longId=124027, objectId=be6212402ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be6212402ecd, replyNumber=0, likeNumber=71, createdTime=2017-12-21, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be6212402ecd, moduleTitle=FDA对阿斯利康肿瘤治疗的Tagrisso进行优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=be6212402ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385795, encodeId=cf3a1385e9569, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请, objectType=article, longId=122074, objectId=1ca11220e4f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ca11220e4f0, replyNumber=0, likeNumber=71, createdTime=2017-12-03, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ca11220e4f0, moduleTitle=欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1ca11220e4f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385794, encodeId=c9451385e9490, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=肺癌重磅消息！阿斯利康第三代靶向肺癌药物Tagrisso获中国CFDA批准, objectType=article, longId=94068, objectId=ee9c9406868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9c9406868, replyNumber=0, likeNumber=75, createdTime=2017-04-01, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9c9406868, moduleTitle=肺癌重磅消息！阿斯利康第三代靶向肺癌药物Tagrisso获中国CFDA批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ee9c9406868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385793, encodeId=72571385e93e7, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月, objectType=article, longId=66570, objectId=3bc2665e07d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bc2665e07d, replyNumber=0, likeNumber=76, createdTime=2016-04-17, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bc2665e07d, moduleTitle=ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3bc2665e07d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1385792, encodeId=a9401385e922b, content=<a href='/topic/show?id=77371e08996' target=_blank style='color:#2F92EE;'>#Tagrisso#</a>, objectTitle=阿斯利康非小细胞肺癌口服新药Tagrisso获FDA批准上市, objectType=article, longId=59138, objectId=9a155913856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a155913856, replyNumber=0, likeNumber=70, createdTime=2015-11-21, rootId=0, userName=tsing_hit, userId=dcaa509, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a155913856, moduleTitle=阿斯利康非小细胞肺癌口服新药Tagrisso获FDA批准上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9a155913856)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Tagrisso

2020-05-29

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期

2021-02-02

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

阿斯利康的Tagrisso在美国被批准作为NSCLC的辅助疗法

2020-12-21

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效

2020-04-13

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌

2019-09-07

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

中国监管机构批准阿斯利康的Tagrisso作为EGFR突变型NSCLC的一线治疗药物

2019-09-06

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2019-08-12

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

AZ的肺癌药物Tagrisso在欧洲获准作为一线用药

2018-05-03

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

AZ的Tagrisso作为肺癌一线用药在美国获批

2018-04-22

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

AZ的Tagrisso对肺癌的治疗具有持续作用

2018-04-18

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

FDA对阿斯利康肿瘤治疗的Tagrisso进行优先审查

2017-12-21

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请

2017-12-03

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

肺癌重磅消息！阿斯利康第三代靶向肺癌药物Tagrisso获中国CFDA批准

2017-04-01

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月

2016-04-17

tsing_hit (审核中...)

前往app查看评论内容

#Tagrisso#

阿斯利康非小细胞肺癌口服新药Tagrisso获FDA批准上市

2015-11-21

科室
- - 订阅+
  - 更多科室
工具
服务